시장보고서
상품코드
1954341

조직병리학 서비스 시장 분석 및 예측(-2035년) : 유형별, 제품 유형별, 서비스별, 기술별, 용도별, 최종 사용자별, 구성 요소별, 프로세스별, 설비별, 솔루션별

Histopathology Services Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Component, Process, Equipment, Solutions

발행일: | 리서치사: Global Insight Services | 페이지 정보: 영문 326 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 조직병리학 서비스 시장은 2024년 352억 달러에서 2034년까지 675억 달러로 확대되어 CAGR 약 6.6%를 나타낼 것으로 예측됩니다. 조직병리학 서비스 시장은 질병(특히 암)의 특정을 목적으로 한 조직 분석에 초점을 맞춘 진단 및 조사 서비스를 포함합니다. 이러한 서비스에는 생검 처리, 염색, 현미경 검사가 포함되며 정확한 진단 및 치료 계획에 필수적입니다. 시장은 암의 유병률 상승, 진단 기술의 진보, 맞춤형 의료에 대한 수요 증가에 의해 견인되고 있습니다. 주요 동향으로는 디지털 병리학, AI 통합, 전문 공급자에게 조직병리학 서비스의 아웃소싱이 포함되어 효율성과 진단 정확도가 향상됩니다.

조직병리학 서비스 시장은 진단 기술의 진보와 정밀의료에 대한 수요 증가를 배경으로 현저한 성장을 이루고 있습니다. 면역조직화학 분야는 진단 정밀도와 특이성의 향상에 의해 높은 실적을 나타내고 있습니다. 디지털 병리학은 원격 진료의 촉진과 워크플로우의 효율화가 가능하기 때문에 이에 계속되고 있습니다. 분자 병리학은 유전자 및 분자 분석에 초점을 맞추고 있으며, 개인화 치료 전략으로의 전환을 반영하여 주목을 받고 있습니다. 하위 부문 중에서는 암 진단이 여전히 가장 높은 성과를 나타내고 있으며, 암 발생률의 상승과 조기 발견의 필요성에 의해 추진되고 있습니다. 전염병 진단은 유행 대책과 신속한 병원체 동정에 대한 세계적 관심 증가를 배경으로 2위 성장 부문으로서 상승하고 있습니다. AI를 활용한 영상 해석이나 자동 검체 처리 등의 기술 혁신이 시장 역학을 더욱 가속화하고 있습니다. 원격병리 진단과 클라우드 기반 데이터 관리 솔루션의 통합으로 서비스 제공 최적화와 시장 기회 확대가 진행되고 있습니다.

시장 세분화
유형 임상 조직병리학, 수의 조직병리학, 포렌식 조직병리학
제품 장비, 소모품, 시약, 항체, 프로브, 염색제, 키트
서비스 통상 조직병리학, 면역 조직 화학, In Situ Hybridization(ISH), 디지털 병리학, 컨설팅 서비스, 바이오 뱅킹
기술 광학 현미경, 전자 현미경, 공초점 현미경, 형광 현미경
응용 분야 질병 진단, 신약개발, 조사, 바이오마커 식별, 종양학, 신경학, 심장학
최종 사용자 병원, 진단실험실, 학술 연구소, 제약 회사, 생명 공학 회사, 위탁 연구 기관
구성요소 하드웨어, 소프트웨어, 서비스
설치 유형 On-Premise, 클라우드 기반
솔루션 통합 솔루션, 독립형 솔루션

조직병리학 서비스 시장은 전략적 가격 설정과 혁신적인 제품 투입으로 시장 점유율의 역동적인 변화를 경험하고 있습니다. 각사는 경쟁 우위성을 획득하기 위해 서비스 제공 내용의 강화에 주력하고 있습니다. 진단 정밀도와 턴어라운드 타임의 개선에 중점을 두고 있어 의료 제공업체로부터의 큰 관심을 모으고 있습니다. 이 분야에서는 맞춤형 의료에 대한 수요가 급증하고 있으며, 첨단 조직병리학 기술의 도입을 촉진하고 있습니다. 시장은 경쟁적인 가격 전략이 특징이며, 이러한 서비스를 세계적으로 널리 이용 가능하게 하고, 보급을 촉진하고 있습니다. 경쟁 벤치마킹 조사에 의하면, 기존 기업이 시장을 독점하는 상황이면서, 신규 참가 기업이 혁신적인 기술로 큰 진전을 보이고 있습니다. 규제의 영향은 매우 중요하며, 엄격한 지침이 품질과 안전성을 확보하고 시장 역학에 영향을 미치고 있습니다. 북미와 유럽 등 지역의 규제 프레임워크는 특히 영향력이 크고 기준과 시장 진출 전략을 형성하고 있습니다. 신흥 시장도 기세를 늘리고 있으며, 확대를 위한 유망한 기회를 제공합니다. 경쟁과 규제의 상호 작용이 혁신을 촉진하고 시장을 성장과 발전의 유망한 궤도로 이끌고 있습니다.

주요 동향과 촉진요인:

조직병리학 서비스 시장은 맞춤형 의료의 진전과 암 이환율의 상승을 배경으로 현저한 성장을 보이고 있습니다. 주요 동향으로는 진단 프로세스에 인공지능(AI)의 통합을 들 수 있으며, 정밀도와 효율성의 향상을 도모하고 있습니다. 이 기술 도입으로 업무 흐름이 간소화되고 진단 오류가 줄어들어 환자의 치료 성과가 향상되었습니다. 또한 비용 효율적인 솔루션과 전문 지식의 필요성 때문에 조직병리학 서비스의 외부 위탁이 중시되는 경향이 있습니다. 시장 성장 촉진요인으로는 암 조기 발견에 대한 수요 증가와 고령 인구의 확대를 들 수 있습니다. 이러한 요인은 정확하고 신속한 진단 서비스의 필요성을 높입니다. 또한 새로운 바이오마커와 표적요법의 개발이 조직병리학의 한계를 넓혀 시장 확대의 새로운 길을 창출하고 있습니다. 품질 보증과 규제 준수에 중점화도 시장 역학을 뒷받침하고 있습니다. 의료 인프라가 급속히 발전하는 신흥 시장에는 수많은 기회가 있습니다. 혁신적이고 확장 가능한 솔루션을 제공하는 기업은 이러한 지역의 고급 진단 서비스에 대한 수요 증가를 포착하는 태세를 갖추고 있습니다. 또한 의료 제공업체와 기술 기업 간의 파트너십 및 협업이 혁신을 촉진하고 조직병리학 서비스 시장 전망 성장을 도모하고 있습니다.

목차

제1장 주요 요약

제2장 시장 하이라이트

제3장 시장 역학

  • 거시경제 분석
  • 시장 동향
  • 시장 성장 촉진요인
  • 시장 기회
  • 시장 성장 억제요인
  • CAGR : 성장 분석
  • 영향 분석
  • 신흥 시장
  • 기술 로드맵
  • 전략적 프레임워크

제4장 부문 분석

  • 시장 규모 및 예측 : 유형별
    • 임상 조직병리학
    • 수의 조직병리학
    • 포렌식 조직병리학
    • 기타
  • 시장 규모 및 예측 : 제품별
    • 기기
    • 소모품
    • 시약
    • 항체
    • 프로브
    • 염색제
    • 키트
    • 기타
  • 시장 규모 및 예측 : 서비스별
    • 통상 조직병리학
    • 면역조직 화학
    • In Situ Hybridization(ISH)
    • 디지털 병리학
    • 컨설팅 서비스
    • 바이오뱅킹
    • 기타
  • 시장 규모 및 예측 : 기술별
    • 광학 현미경
    • 전자 현미경
    • 공초점 현미경
    • 형광 현미경
    • 기타
  • 시장 규모 및 예측 : 용도별
    • 질병 진단
    • 신약개발
    • 연구
    • 바이오마커 식별
    • 종양학
    • 신경학
    • 심장병학
    • 기타
  • 시장 규모 및 예측 : 최종 사용자별
    • 병원
    • 진단실험실
    • 학술연구기관
    • 제약기업
    • 바이오테크놀러지 기업
    • 수탁연구기관
    • 기타
  • 시장 규모 및 예측 : 컴포넌트별
    • 하드웨어
    • 소프트웨어
    • 서비스
    • 기타
  • 시장 규모 및 예측 : 설치 유형별
    • On-Premise
    • 클라우드 기반
    • 기타
  • 시장 규모 및 예측 : 솔루션별
    • 통합 솔루션
    • 독립형 솔루션
    • 기타

제5장 지역별 분석

  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 라틴아메리카
    • 브라질
    • 아르헨티나
    • 기타 라틴아메리카
  • 아시아태평양
    • 중국
    • 인도
    • 한국
    • 일본
    • 호주
    • 대만
    • 기타 아시아태평양
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 스페인
    • 이탈리아
    • 기타 유럽
  • 중동 및 아프리카
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 남아프리카
    • 사하라 이남 아프리카
    • 기타 중동 및 아프리카

제6장 시장 전략

  • 수요 및 공급의 갭 분석
  • 무역 및 물류상의 제약
  • 가격, 비용, 마진의 동향
  • 시장 침투
  • 소비자 분석
  • 규제 개요

제7장 경쟁 정보

  • 시장 포지셔닝
  • 시장 점유율
  • 경쟁 벤치마킹
  • 주요 기업의 전략

제8장 기업 프로파일

  • Sonic Healthcare
  • Charles River Laboratories
  • Eurofins Scientific
  • Laboratory Corporation of America Holdings
  • Quest Diagnostics
  • Neo Genomics Laboratories
  • Bio-Reference Laboratories
  • ACM Global Laboratories
  • Unilabs
  • Cerba Healthcare
  • Genomic Health
  • Path Group
  • Histopathology Services
  • Labco
  • Bioclinica
  • Medpace
  • Amedes
  • Synlab
  • King Med Diagnostics
  • Targos Molecular Pathology

제9장 당사에 대해서

JHS 26.03.17

Histopathology Services Market is anticipated to expand from $35.2 billion in 2024 to $67.5 billion by 2034, growing at a CAGR of approximately 6.6%. The Histopathology Services Market encompasses diagnostic and research services focused on tissue analysis to identify diseases, particularly cancer. These services include biopsy processing, staining, and microscopic examination, essential for accurate diagnosis and treatment planning. The market is driven by rising cancer prevalence, advancements in diagnostic technology, and increasing demand for personalized medicine. Key trends include digital pathology, AI integration, and outsourcing of histopathology services to specialized providers, enhancing efficiency and diagnostic accuracy.

The Histopathology Services Market is experiencing notable growth, driven by advancements in diagnostic techniques and increasing demand for precision medicine. The segment of immunohistochemistry leads in performance, offering enhanced diagnostic accuracy and specificity. Digital pathology follows closely, propelled by its ability to facilitate remote consultations and streamline workflows. Molecular pathology, with its focus on genetic and molecular analysis, is gaining traction, reflecting the shift towards personalized treatment strategies. Within the sub-segments, cancer diagnostics remains the top-performing area, fueled by the rising incidence of cancer and the need for early detection. Infectious disease diagnostics emerges as the second highest performing sub-segment, driven by the global emphasis on pandemic preparedness and rapid pathogen identification. Technological innovations, such as AI-driven image analysis and automated sample processing, are further enhancing market dynamics. The integration of telepathology and cloud-based data management solutions is optimizing service delivery and expanding market opportunities.

Market Segmentation
TypeClinical Histopathology, Veterinary Histopathology, Forensic Histopathology
ProductInstruments, Consumables, Reagents, Antibodies, Probes, Stains, Kits
ServicesRoutine Histopathology, Immunohistochemistry, In Situ Hybridization, Digital Pathology, Consultation Services, Biobanking
TechnologyLight Microscopy, Electron Microscopy, Confocal Microscopy, Fluorescence Microscopy
ApplicationDisease Diagnosis, Drug Discovery, Research, Biomarker Identification, Oncology, Neurology, Cardiology
End UserHospitals, Diagnostic Laboratories, Academic and Research Institutes, Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations
ComponentHardware, Software, Services
Installation TypeOn-premise, Cloud-based
SolutionsIntegrated Solutions, Standalone Solutions

The histopathology services market is experiencing dynamic shifts in market share, driven by strategic pricing and innovative product launches. Companies are focusing on enhancing their service offerings to gain a competitive edge. The emphasis is on improving diagnostic accuracy and turnaround times, which has attracted significant interest from healthcare providers. This sector is witnessing a surge in demand for personalized medicine, propelling the introduction of advanced histopathology techniques. The market is characterized by a competitive pricing strategy, enabling wider accessibility and adoption of these services globally. Competitive benchmarking reveals a landscape dominated by established players, yet new entrants are making significant inroads with disruptive technologies. Regulatory influences are pivotal, with stringent guidelines ensuring quality and safety, impacting market dynamics. The regulatory framework in regions like North America and Europe is particularly influential, shaping standards and market entry strategies. Emerging markets are also gaining traction, presenting lucrative opportunities for expansion. The interplay of competition and regulation is fostering innovation, driving the market toward a promising trajectory of growth and development.

Geographical Overview:

The histopathology services market is witnessing varied growth across regions, with distinct opportunities emerging. North America leads, driven by advanced healthcare infrastructure and a strong focus on research and development. The presence of key market players and increasing cancer prevalence further bolster this region's growth. Europe follows, with significant investments in healthcare and a rising demand for personalized medicine. The region's emphasis on technological advancements in diagnostics enhances its market potential. In Asia Pacific, rapid urbanization and growing healthcare expenditure drive market expansion. Countries like China and India are at the forefront, investing heavily in healthcare infrastructure. Latin America and the Middle East & Africa present new growth pockets. In Latin America, improving healthcare facilities and rising awareness of early disease detection contribute to market growth. Meanwhile, the Middle East & Africa are seeing increased investments in healthcare, recognizing the potential of histopathology services in improving diagnostic accuracy and patient outcomes.

The global histopathology services market is intricately influenced by tariffs, geopolitical tensions, and supply chain dynamics. In Japan and South Korea, reliance on imports for advanced diagnostic equipment is prompting investments in local manufacturing capabilities to mitigate tariff impacts. China's focus on self-sufficiency is driving domestic innovations in histopathological technologies, while Taiwan, with its robust semiconductor industry, plays a pivotal role in supplying critical components but remains vulnerable to cross-strait tensions. The parent market is experiencing steady growth, fueled by advancements in personalized medicine and cancer research. By 2035, the market is expected to evolve towards integrated digital pathology solutions and AI-driven diagnostics. Middle East conflicts, while primarily affecting energy prices, indirectly influence operational costs and supply chain stability across the sector.

Key Trends and Drivers:

The histopathology services market is experiencing a notable surge, propelled by advancements in personalized medicine and rising cancer prevalence. A key trend is the integration of artificial intelligence in diagnostic processes, enhancing accuracy and efficiency. This technological adoption is streamlining workflows and reducing diagnostic errors, thereby improving patient outcomes. Furthermore, there is a growing emphasis on outsourcing histopathology services, driven by the need for cost-effective solutions and specialized expertise. Drivers of market growth include the increasing demand for early cancer detection and the expanding geriatric population. These factors are fueling the need for precise and timely diagnostic services. Additionally, the development of novel biomarkers and targeted therapies is pushing the boundaries of histopathology, creating new avenues for market expansion. The emphasis on quality assurance and regulatory compliance is also bolstering market dynamics. Opportunities abound in emerging markets where healthcare infrastructure is developing rapidly. Companies offering innovative and scalable solutions are poised to capitalize on these regions' growing demand for advanced diagnostic services. Furthermore, partnerships and collaborations between healthcare providers and technology firms are fostering innovation, paving the way for future growth in the histopathology services market.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Component
  • 2.8 Key Market Highlights by Installation Type
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Clinical Histopathology
    • 4.1.2 Veterinary Histopathology
    • 4.1.3 Forensic Histopathology
    • 4.1.4 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Instruments
    • 4.2.2 Consumables
    • 4.2.3 Reagents
    • 4.2.4 Antibodies
    • 4.2.5 Probes
    • 4.2.6 Stains
    • 4.2.7 Kits
    • 4.2.8 Others
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Routine Histopathology
    • 4.3.2 Immunohistochemistry
    • 4.3.3 In Situ Hybridization
    • 4.3.4 Digital Pathology
    • 4.3.5 Consultation Services
    • 4.3.6 Biobanking
    • 4.3.7 Others
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Light Microscopy
    • 4.4.2 Electron Microscopy
    • 4.4.3 Confocal Microscopy
    • 4.4.4 Fluorescence Microscopy
    • 4.4.5 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Disease Diagnosis
    • 4.5.2 Drug Discovery
    • 4.5.3 Research
    • 4.5.4 Biomarker Identification
    • 4.5.5 Oncology
    • 4.5.6 Neurology
    • 4.5.7 Cardiology
    • 4.5.8 Others
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Diagnostic Laboratories
    • 4.6.3 Academic and Research Institutes
    • 4.6.4 Pharmaceutical Companies
    • 4.6.5 Biotechnology Companies
    • 4.6.6 Contract Research Organizations
    • 4.6.7 Others
  • 4.7 Market Size & Forecast by Component (2020-2035)
    • 4.7.1 Hardware
    • 4.7.2 Software
    • 4.7.3 Services
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Installation Type (2020-2035)
    • 4.8.1 On-premise
    • 4.8.2 Cloud-based
    • 4.8.3 Others
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Integrated Solutions
    • 4.9.2 Standalone Solutions
    • 4.9.3 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Component
      • 5.2.1.8 Installation Type
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Component
      • 5.2.2.8 Installation Type
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Component
      • 5.2.3.8 Installation Type
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Component
      • 5.3.1.8 Installation Type
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Component
      • 5.3.2.8 Installation Type
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Component
      • 5.3.3.8 Installation Type
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Component
      • 5.4.1.8 Installation Type
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Component
      • 5.4.2.8 Installation Type
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Component
      • 5.4.3.8 Installation Type
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Component
      • 5.4.4.8 Installation Type
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Component
      • 5.4.5.8 Installation Type
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Component
      • 5.4.6.8 Installation Type
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Component
      • 5.4.7.8 Installation Type
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Component
      • 5.5.1.8 Installation Type
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Component
      • 5.5.2.8 Installation Type
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Component
      • 5.5.3.8 Installation Type
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Component
      • 5.5.4.8 Installation Type
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Component
      • 5.5.5.8 Installation Type
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Component
      • 5.5.6.8 Installation Type
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Component
      • 5.6.1.8 Installation Type
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Component
      • 5.6.2.8 Installation Type
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Component
      • 5.6.3.8 Installation Type
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Component
      • 5.6.4.8 Installation Type
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Component
      • 5.6.5.8 Installation Type
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Sonic Healthcare
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Charles River Laboratories
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Eurofins Scientific
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Laboratory Corporation of America Holdings
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Quest Diagnostics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Neo Genomics Laboratories
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Bio- Reference Laboratories
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 ACM Global Laboratories
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Unilabs
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Cerba Healthcare
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Genomic Health
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Path Group
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Histopathology Services
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Labco
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Bioclinica
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Medpace
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Amedes
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Synlab
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 King Med Diagnostics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Targos Molecular Pathology
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제